HHLR Advisors’s ADC Therapeutics ADCT Stock Holding History

HHLR Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-500,000	Closed	-$2.41M	–	69
2022 Q3	$2.41M	Hold	500,000	–	–	0.06%	51
2022 Q2	$3.98M	Hold	500,000	–	–	0.09%	49
2022 Q1	$7.34M	Hold	500,000	–	–	0.15%	37
2021 Q4	$10.1M	Hold	500,000	–	–	0.16%	49
2021 Q3	$13.6M	Hold	500,000	–	–	0.18%	56
2021 Q2	$12.2M	Hold	500,000	–	–	0.13%	65
2021 Q1	$12.2M	Hold	500,000	–	–	0.12%	58
2020 Q4	$16M	Hold	500,000	–	–	0.13%	64
2020 Q3	$16.5M	Hold	500,000	–	–	0.12%	51
2020 Q2	$23.4M	Buy	+500,000	New	+$19M	0.21%	42

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors's ADCT Position: Q4 2022 in Review

HHLR Advisors sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 500,000 shares — an estimated $2.41M sold.

HHLR Advisors first reported a position in ADCT in Q2 2020 and held it in 10 quarters. The position peaked at $23.4M in Q2 2020. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

HHLR Advisors reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
HHLR Advisors sold 500,000 ADC Therapeutics shares in Q4 2022, an estimated $2.41M.
HHLR Advisors first reported a position in ADC Therapeutics in Q2 2020 and held it in 10 quarters.
HHLR Advisors's ADC Therapeutics position peaked at $23.4M in Q2 2020.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on HHLR Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.